Rozlytrek — Medical Mutual

Initial criteria

• Patient age ≥ 12 years
• Tumor has NTRK gene fusion without a known acquired resistance mutation
• Tumor is metastatic OR surgical resection will likely result in severe morbidity
• Patient has progressed following treatment OR there are no satisfactory alternative therapies

Reauthorization criteria

• Patient has not experienced intolerable side effects
• Patient has had a beneficial response to therapy, per the prescribing physician

Approval duration

1 year